Investor mix
11 investors on record; lead investors include Axil Capital, Mizuho Sc.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 9 | 82% |
| Other / undisclosed | 2 | 18% |
Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract
11 investors on record; lead investors include Axil Capital, Mizuho Sc.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 9 | 82% |
| Other / undisclosed | 2 | 18% |